ArticleBMC cancer2020

RX-5902, a novel β-catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast Cancer.

John J Tentler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.